TGFB1 and metabolic dysfunction-associated steatohepatitis: As such, our data clearly outlined, not only the predominant role that PKCδ plays in TGFβ1-mediated α-SMA expression in NASH, but also that the exogenous administration of PKCδ inhibitor sufficiently blocked the TGFβ1 pathway and the effects of fibrosis.